Figure 1.

CML SPCs are predominantly quiescent. (Ai) Gating strategy for healthy and CML SPCs enriched for CD34⁺38⁻ and CD34⁺38⁺ cells. (ii) Level of BCR-ABL1 and ABL measured in CD34⁺38⁻ and CD34⁺38⁺ cells. (Bi) Representative dot plots showing the cell-cycle phases in healthy and CML SPCs measured by Ki-67/7-AAD staining. N = 1 representative sample shown. (ii) Percentage of healthy (n = 4) and CML (n = 4) SPCs in G0 cell-cycle phase. (C) Phosphorylation of AKT and STAT5 and level of BCL2 measured by fluorescence-activated cell sorting (FACS) in CML CD34⁺38⁻ and CD34⁺38⁺cells. (*P < .05; **P < .01). n.s., not significant; p-AKT, phospho-AKT; p-STAT5, phospho-STAT5.